



1B-365-C100

Monoclonal Antibody to CD33 Biotin conjugated (0.1 mg)

Clone:	HIM3-4
Isotype:	Mouse IgG1
Specificity:	<p>The antibody HIM3-4 reacts with CD33, a 67 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on myeloid progenitors, monocytes, granulocytes, dendritic cells and mast cells; it is absent on platelets, lymphocytes, erythrocytes and hematopoietic stem cells.</p> <p>HLDA V; WS Code M MA112 HLDA VI; WS Code M MA47</p>
Regulatory Status:	RUO
Immunogen:	NFMY-9s human cell line
Species Reactivity:	Human, Non-Human Primates
Preparation:	The purified antibody is conjugated with Biotin-LC-NHS under optimum conditions. The reagent is free of unconjugated biotin.
Concentration:	1 mg/ml
Storage Buffer:	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability:	Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Usage:	<p>Biotinylated antibody is designed for indirect immunofluorescence analysis by Flow Cytometry.</p> <p>Suggested working dilution is 1:1000. Indicated dilution is recommended starting point for use of this product. Working concentrations should be determined by the investigator.</p>
Expiration:	See vial label
Lot Number:	See vial label
Background:	<p>CD33 is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies; these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface. CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia.</p>

For laboratory research only, not for drug, diagnostic or other use.



Antibodies

- References:**
- *Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML: The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. *Eur J Immunol.* 1999 Nov;29(11):3440-9.
 - *Walter RB, Häusermann P, Raden BW, Teckchandani AM, Kamikura DM, Bernstein ID, Cooper JA: Phosphorylated ITIMs Enable Ubiquitylation of an Inhibitory Cell Surface Receptor. *Traffic.* 2007 Dec 18
 - *Orr SJ, Morgan NM, Elliott J, Burrows JF, Scott CJ, McVicar DW, Johnston JA: CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. *Blood.* 2007 Feb 1;109(3):1061-8.
 - *Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
 - *Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).
 - *McCormack E, Mujic M, Osdal T, Bruserud O, Gjertsen BT: Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. *Blood.* 2013 Feb 14;121(7):e34-42. doi: 10.1182/blood-2012-05-429555.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz